Pfizer Says Its SARS-CoV-2 Vaccine Is More Than 90% Effective At Six Months And Protects Against B.1.351 Variant

USA Today (4/1, Weintraub) reports, “Six months after getting a second dose of the Pfizer-BioNTech vaccine as part of a 46,000-person clinical trial, volunteers remained more than 90% protected against symptomatic [SARS-CoV-2 infection] and even better pr...